Radiolabeled Peptide as Diagnostic, Therapeutic, and Theranostic agents for Prostate Cancer: Systematic Literature Review

Penulis

  • Syabrina Salsabilah Gili Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Muslim Indonesia, Makassar
  • Muzakkir Baitz Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Muslim Indonesia, Makassar
  • Nurmaya Effendi Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Muslim Indonesia, Makassar

DOI:

https://doi.org/10.33096/pharmrep.v1i1.174

Kata Kunci:

Radiolabelled-peptide, therapy, diagnosis, prostate cancer

Abstrak

Prostate cancer (PCa) is the most common sex-related malignancy and the second most common cause of mortality after lung cancer for men. Around 61.8% of Indonesian people undergo cancer treatment with surgery. This study aimed to figure out the use of radiolabeled peptides for diagnosis, therapy, and theranostics of prostate cancer. This study performed a literature review by searching the web databases such as PubMed, MDPI, Elsevier (Science Direct), and ACS Publications. The result showed that peptide compounds such RM2, VCN (Vicrostatin), DB15, and BBN7-14 were utilized as radionuclide-carriers for diagnostic imaging, meanwhile, peptides such as NeoBOMB1, PSMA-617, and [RGD-Glu-[DO3A]-6-Ahx-RM2] containing alpha or beta-emitted radionuclide were used as therapeutic and theranostic agents. They were tagged using 68Ga, 161Tb, 177Lu, 64Cu, 124I, 99mTc, 90Y, and 86Y radionuclides. Great efforts have been conducted in developing peptide-based radiopharmaceuticals for diagnosis and therapy of prostate cancer. Research groups focusing in nuclear medicine will continue to develop radiopharmaceuticals in the future, especially radiopeptide compounds for the diagnosis and therapy of prostate cancer.

Referensi

Abouzayed A, Rinne S, Sabahnoo H, Sörensen J, Chernov V, Tolmachev V, Orlova A. Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS/SES-PEG2-RM26 for imaging of prostate cancer. Pharmaceutics. 2021; 13(2): 182.

Awaludin R. Menangani Kanker Dengan Radiopeptida. Buletin Alara. 2006; 8(2): 83-86.

Bandara N, Reynolds TJS, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ. Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer. Nucl Med Biol. 2018; 62-62: 71-77.

Cheng S, Lang L, Wang Z, Jacobson O, Yung B, Zhu G, Gu D, Ma Y, Zhu X, Niu G, Chen X. Positron emission tomography ımaging of prostate cancer with Ga-68-labeled gastrin-releasing peptide receptor agonist BBN7-14 and antagonist RM26. Bioconjug Chem. 2018; 29(2): 410-419.

Dalm SU, Bakker IL, Blois ED, Doeswijk GN, Konijnenberg MW, Orlandi F, Barbato D, Tedesco M, Maina T, Nock BA, Jong MD. 68Ga/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017; 58(2): 293-299.

Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics. 2012; 2(5): 481–501.

Jadvar H, Chen K, Park R, Yap LP, Vorobyova I, Swenson S, Markland FS. Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer. Amino Acids. 2019; 51(10-12): 1569-1575.

Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, Oedegaard C, Saad A, Sandler I, Ben-Haim S, Domachevsky L, Berger R. A retrospective analysis of the safety and activity of lutetium-177-prostate-specific membrane antigen radionuclide treatment in older patients with metastatic castration-resistant prostate cancer. Oncologist. 2020;25(9):787-792.

Li X, Cai H, Wu X, Li L, Wu H, Tian R. New frontiers in molecular imaging using peptide-based radiopharmaceuticals for prostate cancer. Front Chem. 2020; 8: 583309.

Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, Meulen NP. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019; 46(9): 1919-1930.

Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, Jong MD, Maina T, Baum RP. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017; 58(1): 75-80.

Nock BA, Kaloudi A, Kanellopoulos P, Janota B, Bromińska B, Iżycki D, Mikołajczak R, Czepczynski R, Maina T. [99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes. Cancers (Basel). 2021; 13(20): 5093.

Pangribowo, S. Beban kanker di Indonesia. Pus. Data dan Inf. Kemeterian Kesehat. RI 1–16 2019

Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H. response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016 Sep;57(9):1334-8.

Rosilawati N, Nasution I, Murni T. Penggunaan radiofarmaka untuk diagnosa dan terapi di indonesia dan asas keamanan penggunaan obat. Soepra. 2018; 3(1), 60-73.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7-34.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer. Eur Urol Oncol. 2019; 2(2): 166-173.

Velikyan I. Radionuclides for imaging and therapy in oncology. In Cancer Theranostics; Chen, X., Wong, S., Eds.; Elsevier: Amsterdam, The Netherlands, 2014, pp. 285–325

Xia L, Wen L, Meng X, Zhou N, Guo X, Liu T, Xu X, Wang F, Zhu H, Yang Z. Application analysis of 124I-PPMN for enhanced retention in tumors of prostate cancer xenograft mice. Int J Nanomedicine. 2021; 16: 7685-7695.

Unduhan

Diterbitkan

2022-03-02

Terbitan

Vol 1 No 1 (2022): (March) Pharmaceutical Reports

Bagian

Articles

Lisensi

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
  • The author must submit Copyright form After acceptance of the article.